Grace Therapeutics, Inc. (GRCE) Revenue History
Annual and quarterly revenue from 2013 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GRCE Revenue Growth
GRCE Revenue Analysis (2013–2025)
As of May 8, 2026, Grace Therapeutics, Inc. (GRCE) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2026) recorded $0 in revenue.
Looking at the longer-term picture, GRCE's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $707,395 in 2013.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY). Compare GRCE vs RARE →
GRCE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GRCECurrent | $0 | - | - | - | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% |
GRCE Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-16,679,000 | - |
| 2024 | $0 | - | $-11,000 | - | $-11,312,000 | - |
| 2023 | $0 | - | $0 | - | $-52,155,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-15,589,000 | - |
| 2021 | $196K | - | $120K | 61.2% | $-16,419,000 | -8377.0% |
| 2020 | $0 | - | $0 | - | $-24,438,000 | - |
| 2019 | $0 | - | $0 | - | $-34,406,000 | - |
| 2018 | $0 | -100.0% | $0 | - | $-15,252,000 | - |
| 2016 | $28K | -87.2% | $-32,294 | -116.2% | $-7,093,000 | -25526.3% |
| 2015 | $216K | -52.0% | $28K | 13.1% | $-9,907,000 | -4580.5% |
See GRCE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRCE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GRCE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGRCE — Frequently Asked Questions
Quick answers to the most common questions about buying GRCE stock.
Is GRCE's revenue growth accelerating or slowing?
GRCE TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is GRCE's long-term revenue growth rate?
Grace Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is GRCE's revenue distributed by segment?
GRCE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2025 are available for download. Segment mix reveals concentration and diversification trends.